| 39.75 -0.91 (-2.24%) | 08-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
NuVasive, Inc. is a medical technology firm focused on creating, producing, and distributing comprehensive procedural solutions for spinal operations. The company offers a range of surgical access instruments, such as the Maxcess integrated split-blade retractor system, which facilitates less-invasive surgical approaches by significantly reducing soft tissue disruption during spinal procedures. Additionally, NuVasive manufactures specialized spinal implants designed to improve spinal fusion by optimizing the osseointegration and biomechanical characteristics of materials like porous titanium and porous polyetheretherketone. Its fixation systems are engineered to help maintain and re-establish proper patient alignment. Other offerings include cervical total disc replacement technology, used in cervical spinal fusion surgery, and advanced neuromonitoring systems. These systems leverage proprietary software for nerve detection and avoidance, complemented by comprehensive intraoperative neuromonitoring services and support. The Pulse platform, a distinctive software ecosystem, unifies various hardware technologies into a compact, integrated system within the operating room environment. Furthermore, NuVasive supplies expandable growing rod implant systems for managing early-onset scoliosis, along with diverse biologics crucial for supporting spinal fusion or bone healing. Another key product is Precice, an intramedullary implant device that employs MAGEC technology for the non-invasive lengthening of the femur and tibia. The company also offers both onsite and remote monitoring solutions for the neurological systems of patients undergoing spinal and brain-related surgical interventions. NuVasive distributes its products to a broad client base, including patients, surgeons, hospitals, and insurers, through a multi-channel sales approach encompassing independent sales agents, its own sales force, and distributors, operating across the United States and global markets. Established in 1997, NuVasive, Inc. maintains its corporate headquarters in San Diego, California.
Tue, 01 Sep 2026
NuVasive Inc. (NUVA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Thu, 09 Feb 2023
Globus Medical to buy NuVasive in deal valued at about $3 billion - PharmaLive
Thu, 09 Feb 2023
Globus Medical's $3 bln deal for NuVasive to fortify spinal business spooks investors - Reuters
Fri, 30 Jul 2021
NuVasive Receives Latest FDA 510(k) Clearance for Pulse Platform and Announces Commercial Launch - PR Newswire
Wed, 07 Apr 2021
NuVasive’s Simplify Disc Receives FDA Approval for Two-Level Cervical Total Disc Replacement - Ortho Spine News
Wed, 24 Feb 2021
NuVasive Acquires Simplify Medical - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|